Shanghai, China, 28th August 2020. Elpiscience Biopharma Ltd., a clinical stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies, today announced that the Center of Drug Evaluation (CDE) has cleared Elpiscience’s IND application for ES102 to initiate a Phase I clinical trial in China.
ES102 is currently being evaluated in a Phase I study led by Inhibrx in the US. Elpiscience will evaluate the safety, tolerability and explore early efficacy signal of ES102 as single agent or in combination with toripalimab (TUOYI®, an anti-PD-1 mAb) for the treatment of solid tumors and hematological malignancies in China.
Dr. Steve Chin, CMO of Elpiscience, said: “We are excited that the ES102 IND has been cleared by CDE. Different from conventional bivalent OX40 agonists, ES102, is a hexavalent OX40 agonistic antibody which can induce a lotstronger immune activation. We look forward to exploiting its anti-tumor potentials in clinical studies.”
ES102 is a hexavalent OX40 agonistic antibody with a unique “first-in-class” design. The special design of ES102 allows for efficient OX40 agonism even in the absence of exogenous cross-linking. ES102 induces much strong immune activation compared to tetrameric or conventional bivalent OX40 antibodies, it has demonstrated impressive single agent anti-tumor efficacy and great synergy with anti-PD1/PD-L1 agents in preclinical models.